Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Prescription-event monitoring--recent progress and future horizons.

Mann RD.

Br J Clin Pharmacol. 1998 Sep;46(3):195-201. Review. No abstract available.

2.

Prescription-event monitoring: methodology and recent progress.

Rawson NS, Pearce GL, Inman WH.

J Clin Epidemiol. 1990;43(5):509-22.

PMID:
2324790
3.

Adverse drug reaction monitoring in pediatric practice.

Kshirsagar NA, Karande S.

Indian Pediatr. 1996 Dec;33(12):993-8. No abstract available.

PMID:
9141798
4.

International monitoring for adverse drug reactions of long latency.

Fletcher AP, Griffin JP.

Adverse Drug React Toxicol Rev. 1991 Winter;10(4):209-30. Review. No abstract available.

PMID:
1793771
5.

Research methods in drug surveillance.

Engel RR, Grohmann R, RĂ¼ther E, Hippius H.

Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S12-5.

PMID:
15052510
6.

Strategy for surveillance of adverse drug events.

Bright RA.

Food Drug Law J. 2007;62(3):605-16. No abstract available.

PMID:
17915403
7.

Drug prescribing. Licensing flaws.

Watts G.

Health Serv J. 1999 Jan 28;109(5639):suppl 9-11. No abstract available.

PMID:
10345648
8.

Postmarketing surveillance of adverse reactions to drugs.

[No authors listed]

Br Med J (Clin Res Ed). 1984 Apr 14;288(6424):1155-6. No abstract available.

9.

Suspected adverse reactions, 2007.

Dyer F, Spagnuolo-Weaver M, Coolees S, Tait A.

Vet Rec. 2008 Jul 19;163(3):69-72. No abstract available.

PMID:
18702197
10.

Prescription-event and other forms of epidemiological monitoring of side-effects in the UK.

Dunn N, Mann RD.

Clin Exp Allergy. 1999 Jul;29 Suppl 3:217-39.

PMID:
10444241
11.

[Drug-eruptions].

Thielen AM, Toutous-Trellu L, Desmeules J.

Rev Med Suisse. 2008 Jul 16;4(165):1671-5. Review. French.

PMID:
18767294
12.

Terminology in prescription-event monitoring.

Kubota K, Inman WH.

Eur J Clin Pharmacol. 1994;46(6):497-500.

PMID:
7995314
13.

Toward improved adverse event/suspected adverse drug reaction reporting.

Gross R, Strom BL.

Pharmacoepidemiol Drug Saf. 2003 Mar;12(2):89-91. No abstract available.

PMID:
12642971
14.

A model for the future conduct of pharmacovigilance.

Waller PC, Evans SJ.

Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):17-29.

PMID:
12616844
15.

Statistics: detecting a rare adverse drug reaction using spontaneous reports.

Schroeder DR.

Reg Anesth Pain Med. 1998 Nov-Dec;23(6 Suppl 2):183-9. No abstract available.

PMID:
9845392
16.

The demise of postmarketing surveillance.

Fletcher AP.

Adverse Drug React Toxicol Rev. 1995 Spring;14(1):7-9. No abstract available.

PMID:
7612783
17.

The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.

Robb MA, Racoosin JA, Sherman RE, Gross TP, Ball R, Reichman ME, Midthun K, Woodcock J.

Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:9-11. doi: 10.1002/pds.2311. No abstract available.

PMID:
22262587
18.

An underrecognized challenge in evaluating postmarketing drug safety.

Roden DM.

Circulation. 2005 Jan 25;111(3):246-8. No abstract available.

19.

Preventing postmarketing changes in recommended doses and marketing withdrawals.

Peck C.

Ernst Schering Res Found Workshop. 2007;(59):209-16. Review.

PMID:
17117726
20.

Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries.

Griffin JP.

Br J Clin Pharmacol. 1986;22 Suppl 1:83S-100S. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk